Cytotoxic chemotherapeutic agents under development with a possible future role in prostate cancer.
New cytotoxic chemotherapeutic compounds under development or in early clinical trial which might be considered for clinical evaluation in prostatic carcinoma are discussed. The following classes of agents are considered: lipid-soluble antifolates, anthracyclines, nitrosoureas, and platinum analogues. A group of miscellaneous compounds is also discussed.
D000903:Antibiotics, Antineoplastic / Q000627:therapeutic use; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D002945:Cisplatin / Q000627:therapeutic use; D004341:Drug Evaluation; D005493:Folic Acid Antagonists / Q000627:therapeutic use; D006801:Humans; D008297:Male; D009279:Naphthacenes / Q000627:therapeutic use; D009607:Nitrosourea Compounds / Q000627:therapeutic use; D009944:Organoplatinum Compounds / Q000627:therapeutic use; D011471:Prostatic Neoplasms / Q000188:drug therapy*; D012995:Solubility
D000903:Antibiotics, Antineoplastic; D000970:Antineoplastic Agents; D005493:Folic Acid Antagonists; D009279:Naphthacenes; D009607:Nitrosourea Compounds; D009944:Organoplatinum Compounds; D002945:Cisplatin